Latest Asx Reporting News

ASX Limited reported robust half-year results with an 11.2% rise in operating revenue and a steady net profit, while advancing its technology upgrade and responding to regulatory scrutiny.

ASX Limited has posted a solid 8.3% increase in net profit for the half-year ending December 2025, while announcing a reduced dividend payout and the planned departure of its CEO. The company is navigating regulatory scrutiny and investing heavily in technology upgrades.

American Uranium Limited has upgraded its U.S. trading status to the OTCQB Venture Market, enhancing liquidity and accessibility for North American investors. This move supports the company’s strategy to expand its U.S. shareholder base and increase visibility for its flagship uranium project in Wyoming.

Manhattan Gold Limited has reshaped its board and management team following the full acquisition of the Hook Lake Project, signalling a strategic pivot towards advancing this key asset.

Tyranna Resources has withdrawn certain visual mineralisation estimates from its recent quarterly report, citing non-compliance with ASX reporting standards and urging investors to disregard these figures.

PentaNet Ltd reported a positive net operating cash flow of A$710,000 for the December 2025 quarter, alongside a strong cash position of A$2.42 million. The company completed its final payment for a 15-year 5G spectrum license while maintaining access to substantial financing facilities.

ASX Limited has updated its FY26 expense growth guidance upwards, reflecting increased investments in risk management and technology modernisation alongside ASIC Inquiry-related costs, while reporting strong unaudited 1H26 revenue growth.

Triton Minerals Limited has formally retracted certain visual estimates of mineralisation from its recent market update, acknowledging non-compliance with ASX reporting standards and urging investors to disregard these figures.

Tribune Resources has replaced its initial FY2026 Q1 EKJV exploration report with a more detailed version, revealing promising high-grade gold assay results and enhanced compliance disclosures.

Aroa Biosurgery has reported a strong first half for FY26, with 14% revenue growth driven by its Myriad product line and a return to positive EBITDA. The company also secured relief from ASX quarterly reporting requirements, signaling improved financial stability.

HyTerra Limited has begun trading on the US OTCQB Venture Market, opening doors to American investors and supporting its strategic expansion in the burgeoning geologic hydrogen sector.

ASX Limited reaffirms its FY26 expense growth guidance while detailing progress on its five-year transformation and addressing regulatory challenges. Strong FY25 financial results and a robust market pipeline underpin the company’s outlook.